SKN | UBS Calls Ten ETRACS Exchange-Traded Notes for Redemption, Setting a December Exit for Investors

Key Takeaways:

• UBS AG announced the redemption of all outstanding securities across ten ETRACS exchange-traded note (ETN) series listed on NYSE Arca.
• The bank expects settlement on December 17 or 18, 2026, with final payment calculated under the terms of each product’s prospectus supplement.
• UBS cautioned that suspended new issuance could affect secondary-market liquidity and create premiums that may disappear before redemption.

UBS AG has initiated the wind-down of ten exchange-traded note products, announcing on November 12, 2026, that it intends to redeem all outstanding securities across the affected series. The decision is a direct product-level action by the Swiss banking group, with implications for investors holding the notes through brokerage accounts, institutional portfolios or structured investment mandates. While the announcement does not indicate a broader change to UBS’s banking operations or capital position, it establishes a defined timetable for the termination of these securities.

UBS Sets Redemption Timetable Across Ten ETN Series

The ten affected securities are listed on NYSE Arca and issued by UBS AG under its Medium Term Notes, Series B programme. They cover several income-oriented and leveraged strategies, including business development companies, closed-end funds, U.S. dividend equities, mortgage REITs, preferred stocks, master limited partnerships and commodities.

The affected tickers are BDCX, BDCZ, CEFD, HDLB, IFED, MLPR, MVRL, PFFL, SMHB and UCIB. Three products—HDLB, PFFL and SMHB—are expected to have their final trading session on December 16. The remaining seven are expected to stop trading on December 17.

UBS has scheduled the call settlement dates for December 17 or December 18, 2026. Holders will receive the applicable Call Settlement Amount or Redemption Amount, calculated according to the relevant prospectus supplement. The payment is therefore not necessarily equivalent to the last quoted market price or an investor’s original purchase cost.

BDCZ Requires a Separate Formal Notice

UBS has distinguished the treatment of BDCZ from the other nine securities. Its November 12 announcement is an advance notification of the anticipated redemption, rather than the formal call notice required under the applicable prospectus supplement. The bank expects to issue that notice on November 24, 2026.

This distinction matters because the formal notice governs the contractual redemption process and the applicable measurement timetable. For BDCZ, UBS has specified a ten-index-business-day measurement period beginning December 2 and ending December 15, subject to the product documentation. The other affected notes generally use a single index business day or trading day for their measurement period.

UBS Warns That Market Prices May Diverge From Redemption Value

Beyond the timetable, UBS highlighted an important market-structure risk. The discontinuation of further issuance may affect the supply and demand balance for the notes, potentially reducing secondary-market liquidity. In certain circumstances, limited supply could cause an ETN to trade at a premium to its indicative value.

That premium is not guaranteed to survive until redemption. UBS explicitly warned that investors will not receive any additional premium above the contractual Call Settlement Amount or Redemption Amount. An investor purchasing a note above its eventual redemption value could therefore incur a loss even if the underlying reference index performs as expected.

The announcement does not alter existing contractual redemption rights or establish that UBS is withdrawing from the broader ETRACS platform. It is a defined decision affecting ten specific securities. For sophisticated investors, the immediate priority is to reconcile affected holdings against the relevant prospectus terms, final trading dates, valuation periods and settlement amounts. The distinction between market price and contractual redemption value is particularly important for portfolios holding leveraged or income-oriented ETNs. For a confidential discussion regarding structured products and cross-border portfolio oversight, contact our senior advisory team.